Gyre Therapeutics, Inc. GYRE Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $37.5M+149% | $37.07M+214% | $40.4M+155% | $36.49M+127% | $15.05M-49.5% | ||
| $12.31M-17.1% | $15.36M+3.3% | $19.65M— | $17.87M— | $14.85M— | ||
| $104.35M+34.0% | $101.73M+39.1% | $90.25M+30.6% | $83.86M+69.2% | $77.85M+152% | ||
| $39.24M+49.6% | $35.76M+53.6% | $31.93M+50.4% | $29.46M+111% | $26.23M+221% | ||
| $91.73M+34.0% | $102.37M+58.0% | $98.58M+79.9% | $91.29M+70.6% | $68.45M+9.1% | ||
| $23.57M+0.2% | $23.6M-1.2% | $23.61M-3.4% | $23.4M— | $23.52M— | ||
| $4.63M-9.0% | $4.73M+1,632% | $4.85M+2,534% | $4.96M— | $5.08M— | ||
| $162.02M+24.8% | $166.13M+32.5% | $159.38M+27.3% | $152.65M+26.2% | $129.79M+6.4% | ||
| $265K+117% | $124K+14.8% | $556K+83.5% | $71K-73.8% | $122K-63.0% | ||
| $840K+2,900% | $14K-77.0% | $58K-68.6% | $0— | $28K— | ||
| $19.79M+4.2% | $18.29M-6.3% | $15.91M+8.1% | $16.92M+8.6% | $18.99M-2.5% | ||
| $25.03M-1.8% | $23.85M-11.7% | $21.97M-17.9% | $23.2M-15.9% | $25.49M-23.3% | ||
| $91K+4.6% | $91K+5.8% | $91K+7.1% | $91K+7.1% | $87K+2.4% | ||
| -$77.67M-9.8% | -$68.43M+6.8% | -$66.7M+9.1% | -$70.31M+5.6% | -$70.76M+9.3% | ||
| $101.31M+48.7% | $106.03M+67.5% | $101.92M+61.3% | $92.03M+52.5% | $68.12M+20.3% | ||
| $162.02M+24.8% | $166.13M+32.5% | $159.38M+27.3% | $152.65M+26.2% | $129.79M+6.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Gyre Therapeutics, Inc.'s total assets?
- Gyre Therapeutics, Inc. (GYRE) holds $162.0M in total assets, up 24.8% year over year.
- How much debt does Gyre Therapeutics, Inc. have?
- Gyre Therapeutics, Inc. carries $823.0K in total debt against $101.3M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Gyre Therapeutics, Inc. have?
- Gyre Therapeutics, Inc. holds $37.5M in cash and equivalents.
- Can Gyre Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.64 — current assets exceed current liabilities.
- Where does Gyre Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
